Browse > Article
http://dx.doi.org/10.3350/cmh.2017.0016

Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B  

Kim, Hyeji (Department of Internal Medicine, The Catholic University of Korea Incheon St. Mary's Hospital)
Kwon, Jung Hyun (Department of Internal Medicine, The Catholic University of Korea Incheon St. Mary's Hospital)
Kim, Yong Hee (Department of Internal Medicine, The Catholic University of Korea Incheon St. Mary's Hospital)
Nam, Soon Woo (Department of Internal Medicine, The Catholic University of Korea Incheon St. Mary's Hospital)
Lee, Jong Yul (Department of Internal Medicine, The Catholic University of Korea Incheon St. Mary's Hospital)
Jang, Jeong Won (Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital)
Publication Information
Clinical and Molecular Hepatology / v.24, no.4, 2018 , pp. 430-435 More about this Journal
Abstract
Acute-on-chronic liver failure (ACLF) occurs in the presence of a chronic liver disease or cirrhosis, and often results from exacerbation of chronic hepatitis B (CHB). The efficacy of corticosteroid treatment in ACLF patients with underlying CHB remains unclear. We report the case of a 50-year-old woman who experienced ACLF due to CHB exacerbation and was treated with a combination of corticosteroids and nucleot(s)ide analogue (NUC). The patient showed rapid decompensation due to CHB exacerbation. Three months of antiviral therapy produced no improvement in liver function. Combination therapy with corticosteroids and NUC was started, which did result in improvement of liver function. This case shows that the combined therapy of corticosteroids and NUC can be effective in treating ACLF due to CHB exacerbation.
Keywords
Acute-on-chronic liver failure; Chronic hepatitis B; Corticosteroid; Exacerbation; Reactivation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Yasui S, Fujiwara K, Nakamura M, Miyamura T, Yonemitsu Y, Mikata R, et al. Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Viral Hepat 2015;22:94-102.
2 Fujiwara K, Yasui S, Okitsu K, Yonemitsu Y, Oda S, Yokosuka O. The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Gastroenterol 2010;45:1255-1262.   DOI
3 Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.   DOI
4 Sjogren MH, Hoofnagle JH, Waggoner JG. Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Hepatology 1987;7:582-585.   DOI
5 Levy P, Marcellin P, Martinot-Peignoux M, Degott C, Nataf J, Benhamou JP. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology 1990;12:570-574.   DOI
6 Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774-780.   DOI
7 Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol 2008;43:711-719.   DOI
8 Zhang XQ, Jiang L, You JP, Liu YY, Peng J, Zhang HY, et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res 2011;41:46-53.   DOI
9 He B, Zhang Y, Lu MH, Cao YL, Fan YH, Deng JQ, et al. Glucocorticoids can increase the survival rate of patients with severe viral hepatitis B: a meta-analysis. Eur J Gastroenterol Hepatol 2013;25:926-934.   DOI
10 Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320-1328.   DOI
11 Wu CY, Hsiao LT, Chiou TJ, Gau JP, Liu JH, Yu YB, et al. Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B. Leuk Lymphoma 2015;56:2357-2364.   DOI
12 Chemin I, Jeantet D, Kay A, Trepo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease. Antiviral Res 2001;52:117-123.   DOI
13 Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54:236-242.   DOI
14 Ware A, Cuthbert J, Shorey J, Gurian L, Eigenbrodt E, Combes B. A prospective trial of steroid therapy in severe viral hepatitis. The prognostic significance of bridging necrosis. Gastroenterology 1981;80:219-224.   DOI
15 Gregory PB, Knauer CM, Kempson RL, Miller R. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methylprednisolone versus placebo. N Engl J Med 1976;294:681-687.   DOI
16 O'Leary JG, Zachary K, Misdraji J, Chung RT. De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy. Clin Infect Dis 2008;46:e12-e14.
17 Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol 2016;13:131-149.   DOI
18 Murunga E, Andersson M, Rensburg CV. Autoimmune hepatitis: a manifestation of immune reconstitution inflammatory syndrome in HIV infected patients? Scand J Gastroenterol 2016;51:814-818.   DOI